|
EPB41L4B expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62503344114384E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.4432899320127E-15 |
| Normal-vs-Stage2 |
1.70939928878511E-11 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
3.081000E-01 |
| Stage1-vs-Stage3 |
1.788820E-01 |
| Stage1-vs-Stage4 |
2.802000E-04 |
| Stage2-vs-Stage3 |
7.581900E-02 |
| Stage2-vs-Stage4 |
2.480300E-03 |
| Stage3-vs-Stage4 |
3.303800E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.22044604925031E-16 |
| Normal-vs-AfricanAmerican |
8.44549996603661E-09 |
| Normal-vs-Asian |
7.7715611723761E-16 |
| Caucasian-vs-AfricanAmerican |
7.006800E-01 |
| Caucasian-vs-Asian |
9.478600E-01 |
| AfricanAmerican-vs-Asian |
6.954800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.88737914186277E-15 |
| Normal-vs-Female |
1.62481139653892E-12 |
| Male-vs-Female |
4.361000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62592161956354E-12 |
| Normal-vs-Age(41-60Yrs) |
1.62481139653892E-12 |
| Normal-vs-Age(61-80Yrs) |
6.66133814775094E-16 |
| Normal-vs-Age(81-100Yrs) |
7.84080000038045E-07 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.004400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.906400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.283390E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.882600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.030000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.336200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.711500E-02 |
| Classical-VS-Follicular |
5.457000E-03 |
| Classical-VS-Other |
8.833600E-01 |
| Classical-VS-Normal |
1.4432899320127E-15 |
| Tall-VS-Follicular |
2.595400E-04 |
| Tall-VS-Other |
2.342600E-01 |
| Tall-VS-Normal |
1.62447832963153E-12 |
| Follicular-VS-Other |
4.627600E-01 |
| Follicular-VS-Normal |
3.26827453989154E-12 |
| Other-VS-Normal |
1.998160E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.99760216648792E-15 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
1.401280E-03 |
|
|
